• Clinical development


IO101 is a peptide vaccine encompassing an HLA-A2-restricted, 9 amino acid IDO-derived CD8+ T-cell epitope. IO101 is currently in phase II clinical trial.

A first-in-man clinical phase I vaccination trial using IO101 was conducted. The study comprised 15 HLA-A2+ patients with advanced NSCLC who were vaccinated with IO101 in Montanide adjuvant following pre-treatment with topical Imiquimod (Aldara® Cream). The vaccine was well tolerated with manageable side effects and no CTCAE grade 3/4 toxicities.

One patient obtained an objective partial response after demonstrating continuous regression of liver metastases on vaccine treatment for 1 year.

Presently a small phase II study is ongoing in melanoma patients. In this study, IO101 together with an A2 Survivin peptide is used for vaccination in combination with temozolomide chemotherapy treatment.

More information can be found in this recent publication: Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase 


IO102 is a peptide vaccine containing a 21-mer IDO-derived peptide. IO102 is currently in phase I clinical trial.

A first-in-man study has been performed in 10 melanoma patients where treatment with IO102 was combined with treatment with the checkpoint inhibitor, ipilimumab (anti-CTLA4 antibody). There were no safety concerns as no treatment-related grade 3 or 4 toxicity was reported. Four patients had disease stabilization. At first evaluation, five of the ten treated patients were in stable disease, one of which had an unconfirmed partial response.

An IO102 phase II clinical study is planned to be initiated in Q4 2017.

For detailed data, please go to: Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab